Ascent Biomedical Ventures
Overview
Ascent Biomedical Ventures is a venture capital firm that focuses on investing in seed and early-stage biomedical technology companies developing medical devices, bio-pharmaceuticals, healthcare services, and information technology. The firm aims to support innovations that have the potential to advance medical science and improve patient care. It invests in early stage ventures and late stage ventures.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Peerbridge Health | Nov 2019 | Early Funding | Co-investor |
| Ancora Heart | Feb 2008 | Series A | Co-investor |
| Azevan Pharmaceuticals | Oct 2013 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Ascent Biomedical Ventures based?
Ascent Biomedical Ventures is headquartered in New York City, New York, United States.
When was Ascent Biomedical Ventures founded?
Ascent Biomedical Ventures was founded in 2004.
How many portfolio companies does Ascent Biomedical Ventures have?
Ascent Biomedical Ventures has 4 portfolio companies in Caplight's dataset.
What are some companies in Ascent Biomedical Ventures's portfolio?
Portfolio companies visible on Caplight include Peerbridge Health, Ancora Heart, Azevan Pharmaceuticals.
What was Ascent Biomedical Ventures's most recent investment shown here?
Ascent Biomedical Ventures's most recent investment in this portfolio sample was in Peerbridge Health in 2019.
What sectors does Ascent Biomedical Ventures focus on?
Ascent Biomedical Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Ascent Biomedical Ventures focus on?
Ascent Biomedical Ventures typically invests at the MultiStage stage.
What is Ascent Biomedical Ventures's AUM?
Ascent Biomedical Ventures's assets under management are estimated between $50.0M and $100.0M.